Navigation Links
Medisafe 1 Technologies Announces 1-5 Stock Dividend
Date:9/1/2010

ares outstanding to 50,000,000. Medisafe 1 expects the Boards decision will improve liquidity and trading volume in the Company's stock.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact: Jacob Elhadad CEO +972-524440000 jacob.elhadad10@gmail.com
'/>"/>

SOURCE Medisafe 1 Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
2. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
3. Life Technologies and SG Biofuels Complete Sequence of Jatropha Genome
4. Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
5. Looking to leap forward on laser and photodetector technologies
6. MultiCell Technologies Applies for Qualifying Therapeutic Discovery Project Grants
7. Reportlinker Adds Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014)
8. Webcast Alert: Senesco Technologies (SNT) Announces the LHA Life Sciences & Med Tech Day 2010 Presentation
9. OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays
10. SeqWright Expands Genomics Services Offering Through New Partnership With RainDance Technologies
11. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:12/25/2014)... The report “Service Quality Management and Telco ... Type - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” ... and forecasting of revenues. , Browse 152 market ... in-depth TOC on “Service Quality Management (SQM) and Telco ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... HARBIN, China, Sept. 14 /PRNewswire-Asia-FirstCall/ -- ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... American and European fidaxomicin Phase 3 clinical trials ... (CDI) was presented at the 50th Annual Interscience ... Boston. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) ...
... CRANBURY, N.J., Sept. 14 Innophos Holdings, Inc. (Nasdaq: ... today announced that Randy Gress, Chief Executive Officer, will address ... September 30, 2010 at 8:00 a.m. (Eastern Time).   ... event, please go to www.innophos.com Investor Relations Events ...
Cached Biology Technology:Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 2Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 3Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 4Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 5Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 6Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 7Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance 8Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 2Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 3Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 4Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 5Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 6Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC 7
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... National Institutes of Health is making available approximately ... for graduate students and postdoctoral scholars to prepare ... that could take them outside of conventional academic ... Broadening Experience in Scientific Training (BEST) awards are ...
... Geosphere has posted additions to several themed issues: ... Geodynamics and Consequences of Lithospheric Removal in the Sierra ... Snake River Plain-Yellowstone Region and Adjacent Areas; Origin and ... other articles cover terrestrial laser scanning and the earthquake ...
... University scientist Bryan Venters, Ph.D., has shed new light ... begun to explore a possible new approach to treating ... of Molecular Physiology and Biophysics who further developed the ... of Frank Pugh, Ph.D., at Pennsylvania State University before ...
Cached Biology News:NIH announces awards to strengthen the biomedical research workforce 2NIH announces awards to strengthen the biomedical research workforce 3Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 2Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 3Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 4Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 5Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 6Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 7Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 8Geosphere, GSA's dynamic online-only journal posts 9 new articles in Sept. 9Study helps bring genome's 'dark matter' into light 2
Vybrant® Multidrug Resistance Assay Kit...
...
... The CultureWell cell culture systems ... cultured cells for staining and imaging. ... preassembled with standard optical-quality coverslips in ... is provided sterile and ready to ...
... product contains 5 ml of DETACHaBEAD Mouse ... mouse CD4+ T cells from Dynabeads Mouse ... CD4+ T cells from Dynabeads Mouse CD4 ... are suitable for any downstream application including ...
Biology Products: